The estimated Net Worth of James N Topper is at least $101 Milion dollars as of 25 April 2024. James Topper owns over 19 units of AnaptysBio Inc stock worth over $100,724,753 and over the last 19 years he sold ANAB stock worth over $1,227. In addition, he makes $320,236 as Independent Chairman of the Board at AnaptysBio Inc.
James has made over 45 trades of the AnaptysBio Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 19 units of ANAB stock worth $1,227 on 25 April 2024.
The largest trade he's ever made was buying 5,925,926 units of AnaptysBio Inc stock on 14 February 2017 worth over $8,000,000. On average, James trades about 90,999 units every 65 days since 2005. As of 25 April 2024 he still owns at least 2,829,347 units of AnaptysBio Inc stock.
You can see the complete history of James Topper stock trades at the bottom of the page.
Dr. James N. Topper M.D., Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Topper has been a partner with Frazier Healthcare since August 2003, serving as General Partner since 2005. Before joining Frazier Healthcare, Dr. Topper served as head of the Cardiovascular Research and Development Division of Millennium Pharmaceuticals, Inc. and ran Millennium San Francisco (formerly COR Therapeutics, Inc.) from 2002 until 2003. Before the merger of COR and Millennium in 2002, Dr. Topper served as the Vice President of Biology at COR from August 1999 to February 2002. Dr. Topper has served as a director at Sierra Oncology, Inc., a public drug development company, since April 2014. Dr. Topper has served on numerous boards of directors, including Amicus Therapeutics, Inc., Amunix Pharmaceuticals, Inc., Mavupharma, Inc., Phathom Pharmaceuticals, Inc., and Portola Pharmaceuticals, Inc. Dr. Topper received his M.D. and Ph.D. in biophysics from Stanford University and his B.S. in biology from the University of Michigan. Our board of directors believes that Dr. Topper’s experience overseeing Frazier Healthcare investments in biotechnology, senior-management experience in our industry, significant knowledge of medical and scientific matters affecting our business, and understanding of our industry provide him with the qualifications and skills to serve on our board of directors.
As the Independent Chairman of the Board of AnaptysBio Inc, the total compensation of James Topper at AnaptysBio Inc is $320,236. There are 5 executives at AnaptysBio Inc getting paid more, with Hamza Suria having the highest compensation of $7,875,190.
James Topper is 58, he's been the Independent Chairman of the Board of AnaptysBio Inc since 2019. There are 5 older and 8 younger executives at AnaptysBio Inc. The oldest executive at AnaptysBio Inc is Hollings Renton, 73, who is the Lead Independent Director.
James's mailing address filed with the SEC is C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK,, NJ, 07932.
Over the last 8 years, insiders at AnaptysBio Inc have traded over $37,024,151 worth of AnaptysBio Inc stock and bought 5,919,575 units worth $115,520,117 . The most active insiders traders include Holdings A/S Novo, Capital, Llc Eco R1 oraz James N Topper. On average, AnaptysBio Inc executives and independent directors trade stock every 40 days with the average trade being worth of $4,143,306. The most recent stock trade was executed by Paul F. Lizzul on 14 August 2024, trading 2,000 units of ANAB stock currently worth $37,000.
founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c
AnaptysBio Inc executives and other stock owners filed with the SEC include: